Prof. Lucyna Kepka
Radiation Oncology Department, Military Institute of Medicine, Warsaw, Poland.
Special Issue Introduction
Radiotherapy is widely used for the treatment of brain metastases from lung cancer (both small and non-small cell). Survival after development of brain metastases is poor. However, with the advances in immunotherapy and molecular targeted therapies, some patients may achieve a long-term survival even with disseminated disease. For such patients, the neurotoxicity of whole brain radiotherapy (WBRT) is of particular concern and there is a need to use more focused forms of radiotherapy as radiosurgery, or hippocampal-sparing. In some patients, radiotherapy of brain may be avoided. Others benefit from radiotherapy in form of WBRT or radiosurgery or both. In this Special Issue, we aim to present an available evidence as well as areas of research on radiotherapy of brain metastases from lung cancer.
Topics include but are not limited to:
• Incorporation of molecular alterations of NSCLC in making treatment decisions of brain metastases
• WBRT as still valid option for brain metastases from lung cancer
• Avoidance of WBRT in brain metastases from lung cancer in patients available for neurosurgery or radiosurgery
• Avoidance of WBRT in brain metastases from lung cancer in patients who are not available for neurosurgery or radiosurgery
Lung cancer, brain metastases, whole-brain radiotherapy, radiosurgery
31 Dec 2018